Program Description
Presented by The Johns Hopkins University School of Medicine.
This activity is supported by an educational grant from Lilly USA, LLC. For further information concerning Lilly grant funding visit, www.lillygrantoffice.com.
STATEMENT OF NEED
New treatments and methods for improving the care of patients with non-small-cell lung cancer (NSCLC) are continually being investigated. This includes studies of the potential benefits of using histologic markers to target treatment, updating chemotherapy regimens, and the role of novel therapeutic agents. As the field rapidly evolves, guidelines are also being updated almost every year, providing a wealth of new information for oncology clinicians.
The following segment focuses on the importance of personalized medicine in the treatment of NSCLC. This discussion is hosted by David S. Ettinger, MD, FACP, FCCP, Alex Grass Professor of Oncology, Professor of Medicine, and Professor of Radiation Oncology and Molecular Radiation Sciences at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Dr Ettinger will speak with Edward S. Kim, MD, Assistant Professor in the Department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center.
Hosted by
David S. Ettinger, MD
Learning Objectives
At the conclusion of this activity, participants should be able to:
- DESCRIBE the prognostic and predictive role of histology in NSCLC.
- DETERMINE optimal duration of first-line therapy for patients with advanced NSCLC.
- EVALUATE current and emerging therapeutic strategies that combine targeted agents with chemotherapy.
The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.
Target Audience
This activity is designed for oncologists, hematologists, oncology nursing professionals, and internists involved in the management and treatment of NSCLC. No prerequisites are required.
Faculty/Disclosures
Full Disclosure Policy Affecting CME Activities: As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine to require the disclosure of the existence of any relevant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The presenting faculty reported the following:
Program Chair:
David S. Ettinger, MD, FACP, FCCP (Chair)
Alex Grass Professor of Oncology
Professor of Medicine
Professor of Radiation Oncology and Molecular Radiation Sciences
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, MD
Dr Ettinger reports serving as a consultant for and receiving honoraria from AstraZeneca, Bristol-Myers Squibb Company, Celgene, Eli Lilly and Company, Eisai, Genentech, Inc, GlaxoSmithKline, ImClone Systems, Inc, Merck & Co, Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc, and Sanofi-Aventis.
Edward S. Kim, MD
Assistant Professor
Department of Thoracic Head and Neck Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
Dr Kim reports receiving grants/research support from AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, Genentech/OSI, and Sanofi-Aventis.
Off-Label Product Discussion: The audience is advised that a case in this CE activity contains reference(s) to unlabeled or unapproved uses of drugs or devices.
Dr Kim-bevacizumab, erlotinib, and pemetrexed.
All other faculty have indicated that they have not referenced unlabeled/unapproved uses of drugs or devices.
Note: Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution which receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).
Accreditation
CME Information
Accreditation Statement
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Release date: August 24, 2009. Expiration date: August 24, 2010.
Estimated time to complete activity: 15 minutes.
Legal Disclaimer
Disclaimer Statement
The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This enduring material is produced for educational purposes only. Use of The Johns Hopkins University School of Medicine name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.
Internet CME Policy
The Office of Continuing Medical Education (CME) at The Johns Hopkins University School of Medicine is committed to protect the privacy of its members and customers. Johns Hopkins University School of Medicine CME maintains its Internet site as an information resource and service for physicians, other health professionals, and the public. CME at The Johns Hopkins University School of Medicine will keep your personal and credit information confidential when you participate in a CME Internet-based activity. Your information will never be given to anyone outside of The Johns Hopkins University School of Medicine's CME activity. CME collects only the information necessary to provide you with the services that you request.